Reporting for Pharma That Shows Coverage Gaps and Stockists Who Stopped Ordering

Pharma sales reporting has a long tradition of measuring effort. Calls made, days in field, reports filed. None of it answers the two questions an area manager actually needs settled before the next cycle: which accounts have not been reached, and which accounts have stopped buying. The set below is built around those, with institutional business kept in its own lane.

Coverage against the listed plan

Listed accounts in the territory, and which of them were genuinely visited this cycle. It decides the routing and the accountability conversation. A bad number is a healthy visit count with a poor coverage percentage, which means the same accessible accounts are being revisited while the harder half of the territory is untouched.

Stockist and chemist ordering gaps

Accounts measured against their own ordering rhythm, listed when they exceed it. It decides the call list for the week. A bad number is several established accounts quiet simultaneously, which is generally either a credit issue, a competitor scheme or a supply problem, and all three are worth knowing about early.

Product mix by territory

Value and volume split by product, at territory level rather than nationally. It decides where detailing support and training go. A bad number is a territory meeting value target with no contribution from recent introductions, which is the most comfortable way to underperform on strategy while looking fine on the summary.

Institutional pipeline and contract expiry

Tenders by stage and outcome, alongside rate contracts by remaining supply period. It decides where senior time goes. A bad number is a set of contracts expiring within a quarter with no engagement logged, because institutional accounts are far cheaper to retain than to win back once a competitor has supplied them.

Non-conversion reasons

Why orders did not happen, from a closed list. It decides pricing, credit policy and availability conversations. A bad number is stock availability appearing frequently, which is not a sales failure at all and needs to be visible to the supply team in the same review rather than absorbed as a field excuse.

Coverage against plan. It reuses the reporting the field already produces, it takes one cycle to become accurate, and it corrects the most misleading metric in the industry. Ordering gaps come second and require nothing new if secondary or order data is already flowing into the system.

A pharma report that ends in a percentage on a slide has not finished its job. Each of these should end in a named account and a named person.

A maintained account list per territory, because coverage against plan is meaningless if the plan is out of date. One owner per account. Orders recorded against the account rather than aggregated at depot level only. Products held as structured items so mix can be grouped. Tender stages logged as they happen rather than reconstructed after an award. Non-conversion reasons from a closed list. Contract start and end dates on institutional accounts.

Daily call reports summarised into monthly averages, days in field per representative and a chart of sales by month are produced diligently across the industry and change very little. Effort measures reward compliance with a process rather than results from it. If a report can be satisfied by visiting easy accounts and filing on time, it is measuring administration. Keep the ones that name accounts and drop the ones that rank people on activity alone.

It does not manage batches, depot or stockist inventory, invoicing, credit notes, expiry handling or your books, and it does not attempt to hold the statutory records your distribution and accounting systems maintain. This is the commercial view of coverage, ordering and institutional business that sits on top of them.

Read next: all CRM features, lead management software, sales automation, CRM with WhatsApp, CRM versus spreadsheets, CRM by industry, and India pricing.